Рецепт. 2018; : 551-556
Опыт применения L-карнитина в лечении неалкогольной жировой болезни печени
Аннотация
В настоящее время неалкогольная жировая болезнь печени является одним из самых распространенных заболеваний в гепатологии, приводящим к ухудшению качества жизни, инвалидизации и смертности, что в первую очередь обусловлено высоким риском прогрессирования с развитием печеночной недостаточности и гепатоцеллюлярной карциномы. Целью данной статьи является определение возможности использования L-карнитина в лечении стеатогепатита у пациентов с неалкогольной жировой болезнью печени.
Список литературы
1. AGA. (2012) The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, 142:1592–1609.
2. Ludwig J. (1980) No-nalcoholic steatohepatitis. Mayo Clin. Proc., 55:434–438.
3. Adams L, Angulo P. (2006) Treatment of non-alcoholic fatty liver disease. Postgraduate Med. J., 82:315–322.
4. Jakovleva LV, Bezchasnuk ЕМ, Ulesov АV. (2011) L-carnitin: svoistva, preparaty, medicinskoe primenenie [L-carnitine: properties, drugs, medical use]. Ukr. journ. clin. and lab. med., 6(2):17–24.
5. Kopelevich VM. (2005) Vitaminopodobnie soedinenija L-carnitin i acetil-L-carnitin: ot biohimicheskih issledovanij k medicinskomy primeneniu [Vitamin-like compounds L-carnitine and acetyl-L-carnitine: from biochemical studies to medical use]. Ukr. biochem. journ., 77(4):30–50.
6. Efi mova EV, Guskova TA, Kopelevich VM, Gunar VI. (2002) Acetyl-L-carnitin: biolgicheskie svoistva i klinicheskoe primenenie [Acetyl-L-carnitine: biological properties and clinical application]. Chemic-pharmaceutic journ., 36(3):3–7.
7. Gubergric NB, Golubova ОА, Lukashevich GM. (2012) L-carnitin: ot biohimicheskih svojstv k klinicheskomy primeneniu [L-carnitine: from biochemical properties to clinical use]. Modern gastroenterology, 2(64):114–121.
8. Vidal-Casariego A. (2013) Metabolic eff ects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis. Exp Clin Endocrinol Diabetes., 121(4):234–238.
9. Serban M.C. (2016) Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Sci Rep., 12(6):19188. doi: 10.1038/ srep19188.
10. Hong E.S. (2014) Eff ect of carnitine-orotate complex on glucose metabolism and fatty liver: a double-blind, placebo-controlled study. J Gastroenterol Hepatol., 29(7):1449–1457. doi: 10.1111/jgh.12536.
11. Malaguarnera M. (2010) L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis – a randomized and controlled clinical trial. Am J Gastroenterol., 105(6):1338–1345. doi: 10.1038/ajg.2009.719. Epub 2010 Jan 12.
12. Harchenko NV, Skrypnik IN, Harchenko VV. (2017) Nealcogolnaja girovaja bolezn pecheni: terapevticheskie vozmognosti L-carnitina [Non-alcoholic fatty liver disease: the therapeutic potential of L-carnitine]. Gastroenterology, hepatology, coloproctology, 1(43):28–30.
13. Li JL, Wang QY, Luan HY, Kang ZC, Wang CB. (2012) Eff ects of L-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha. Journal of Biomedical Science, 19:32.
14. Somi MH, Fatahi E, Panahi J, Havasian MR, Judaki A. (2014) Data from a randomized and controlled trial of L-carnitine prescription for the treatment for Non-Alcoholic Fatty Liver Disease. Bioinformation, 10(9):575–579.
15. ЕASL-EASD-EASO. (2016) Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol., 64:1388–1402.
Recipe. 2018; : 551-556
Experience of L-carnitine use in the treatment of non-alcoholic fatty liver disease
Abstract
Nowadays non-alcoholic fatty liver disease is one of the most widespread diseases in hepatology, leading to life deterioration, disability and death rate that fi rst of all is caused by high progressing risk with development of hepatic insuffi ciency and hepatocellular carcinoma. The aim of this article is to determine the possibility of L-carnitine using in the treatment of steatohepatitis in patients with non-alcoholic fatty liver disease.
References
1. AGA. (2012) The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, 142:1592–1609.
2. Ludwig J. (1980) No-nalcoholic steatohepatitis. Mayo Clin. Proc., 55:434–438.
3. Adams L, Angulo P. (2006) Treatment of non-alcoholic fatty liver disease. Postgraduate Med. J., 82:315–322.
4. Jakovleva LV, Bezchasnuk EM, Ulesov AV. (2011) L-carnitin: svoistva, preparaty, medicinskoe primenenie [L-carnitine: properties, drugs, medical use]. Ukr. journ. clin. and lab. med., 6(2):17–24.
5. Kopelevich VM. (2005) Vitaminopodobnie soedinenija L-carnitin i acetil-L-carnitin: ot biohimicheskih issledovanij k medicinskomy primeneniu [Vitamin-like compounds L-carnitine and acetyl-L-carnitine: from biochemical studies to medical use]. Ukr. biochem. journ., 77(4):30–50.
6. Efi mova EV, Guskova TA, Kopelevich VM, Gunar VI. (2002) Acetyl-L-carnitin: biolgicheskie svoistva i klinicheskoe primenenie [Acetyl-L-carnitine: biological properties and clinical application]. Chemic-pharmaceutic journ., 36(3):3–7.
7. Gubergric NB, Golubova OA, Lukashevich GM. (2012) L-carnitin: ot biohimicheskih svojstv k klinicheskomy primeneniu [L-carnitine: from biochemical properties to clinical use]. Modern gastroenterology, 2(64):114–121.
8. Vidal-Casariego A. (2013) Metabolic eff ects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis. Exp Clin Endocrinol Diabetes., 121(4):234–238.
9. Serban M.C. (2016) Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Sci Rep., 12(6):19188. doi: 10.1038/ srep19188.
10. Hong E.S. (2014) Eff ect of carnitine-orotate complex on glucose metabolism and fatty liver: a double-blind, placebo-controlled study. J Gastroenterol Hepatol., 29(7):1449–1457. doi: 10.1111/jgh.12536.
11. Malaguarnera M. (2010) L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis – a randomized and controlled clinical trial. Am J Gastroenterol., 105(6):1338–1345. doi: 10.1038/ajg.2009.719. Epub 2010 Jan 12.
12. Harchenko NV, Skrypnik IN, Harchenko VV. (2017) Nealcogolnaja girovaja bolezn pecheni: terapevticheskie vozmognosti L-carnitina [Non-alcoholic fatty liver disease: the therapeutic potential of L-carnitine]. Gastroenterology, hepatology, coloproctology, 1(43):28–30.
13. Li JL, Wang QY, Luan HY, Kang ZC, Wang CB. (2012) Eff ects of L-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha. Journal of Biomedical Science, 19:32.
14. Somi MH, Fatahi E, Panahi J, Havasian MR, Judaki A. (2014) Data from a randomized and controlled trial of L-carnitine prescription for the treatment for Non-Alcoholic Fatty Liver Disease. Bioinformation, 10(9):575–579.
15. EASL-EASD-EASO. (2016) Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol., 64:1388–1402.
